Jiali Li, MD
Hematology/Oncology · Los Gatos
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 32
- 8 carriers
- Office
- 1
Offices
1 location · El Camino Health Medical Network LLC · 202 clinicians in this group
Hospitals listed: El Camino Health · Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
32 plans · 8 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Li’s office at (408) 866-4070 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
32 of 32 plans
| Alignment Health Advantage PPO (PPO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Anthem Full Dual Advantage Aligned (HMO D-SNP) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Medicare Advantage (HMO-POS) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Prime (HMO-POS) | Anthem Blue Cross Partnership Plan | Listed | Oct 3, 2026 |
| Astiva Health C-SNP WOW - NorCal (HMO C-SNP) | Astiva Health | Listed | Sep 27, 2026 |
| Astiva Health Premier Plan - NorCal (HMO) | Astiva Health | Listed | Sep 27, 2026 |
| Astiva Health Savings Plan - NorCal (HMO) | Astiva Health | Listed | Sep 27, 2026 |
| Blue Shield Inspire (HMO) | Blue Shield of California | Listed | Aug 26, 2026 |
| Central Health Classic Care Plan III (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Dual Access Plan (HMO D-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Embrace Care Plan (HMO C-SNP) | Central Health Medicare Plan | Listed, may be out of date | Sep 15, 2025 |
| Central Health Embrace Choice Plan (HMO C-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Valor Care Plan (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence A105831 · Current
Licensed to practise in California · since 2008 · expires 2026-10-31 · Tianjin Medical College.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- El Camino HealthMountain View, CAAcute Care Hospital · Government - Hospital District or Authority · Has an emergency department · Birthing-friendlyPart of El Camino Health, which runs 2 hospitalsPatients rate it 4 of 5 · 80% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.291, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.393, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0, Oct 2024 – Sep 2025
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for El Camino Health
Behind the star rating — Deaths: 3 better, 5 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 1 better, 9 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.291 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.393 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.96 (0.12 to 1.79) · 2,340 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.02 (0.76 to 1.28) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 167.38 (125.03 to 209.73) · 96 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.6 · 68 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 185 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.9 · 814 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13 · 842 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 361 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.6 · 4,633 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.34) · 11,474 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.27 (0.1 to 0.45) · 11,626 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.14 (1.39 to 4.9) · 2,814 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2 (0.61 to 3.39) · 1,327 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.8 to 3.43) · 2,641 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.39 (4.18 to 14.6) · 1,287 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.57 (3.47 to 9.68) · 1,308 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.14 (0.71 to 3.57) · 827 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.6 (0.05 to 1.15) · 9,460 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.5 · 122 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.993 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.706 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.376 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.5 · 218 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.5 · 962 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 3.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -17 · 922 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 18.6 · 860 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.7 · 827 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.1 (4.5 to 8.2) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 13.4 (10.6 to 16.5) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.1 · 144 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.7 · 237 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.8 (10 to 16.1) · 1,639 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.8 to 1.1) · 1,619 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,535 patients answered, 22% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 79% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 76% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 75% |
| Nurses "always" listened carefully | 76% |
| Nurses "always" treated them with courtesy and respect | 87% |
| "Always" quiet at night | 47% |
| "YES", patients would definitely recommend the hospital | 80% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$395,760
Medicare paid this office $395,760 for 623 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Long return visit (40+ min) | 308 | $157,172 | $127 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 102 | $79,870 | $107 |
| Return visit (30+ min) | 337 | $45,546 | $75 |
| Long return visit (40+ min) | 82 | $26,659 | $175 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 113 | $22,742 | $115 |
See all 13 services
| Long return visit (40+ min) | 308 | $157,172 | $127 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 102 | $79,870 | $107 |
| Return visit (30+ min) | 337 | $45,546 | $75 |
| Long return visit (40+ min) | 82 | $26,659 | $175 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 113 | $22,742 | $115 |
| Return visit (30+ min) | 129 | $21,683 | $123 |
| New patient visit (60+ min) | 102 | $16,105 | $158 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 47 | $10,887 | $70 |
| Telephone medical discussion with physician, 21-30 minutes | 19 | $3,734 | $110 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 13 | $2,292 | $135 |
| Telephone medical discussion with physician, 21-30 minutes | 21 | $2,099 | $87 |
| Hospital discharge day management, more than 30 minutes | 12 | $1,711 | $107 |
| New patient visit (45+ min) | 17 | $1,584 | $93 |
Who their Medicare patients are
623 Original Medicare patients in 2024. Average age 77 · Under 65 4% · 85 and older 19% · Women 58% · Also on Medicaid 14% · Health risk score 1.77. At or below the middle of the specialty; the typical hematology-oncology clinician is at 2.04.
Conditions among them: High blood pressure 75% · Cancer 54% · Diabetes 34% · Coronary heart disease 31% · Chronic kidney disease 28% · Atrial fibrillation 21% · Heart failure 19% · COPD 16% · Depression 16% · Stroke 10% · Dementia 8%.
The office billed $1,851,064, Medicare allowed $519,738 and paid $395,760; for 3,539 services of 22 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 623 | 3,539 | 77 | 1.77 | $1,851,064 | $395,760 |
| 2023 | 592 | 3,419 | 77 | 1.68 | $1,719,382 | $367,913 |
| 2022 | 572 | 3,740 | 77 | 1.84 | $1,631,268 | $365,715 |
| 2021 | 523 | 3,442 | 77 | 1.80 | $1,430,003 | $349,938 |
| 2020 | 448 | 2,884 | 77 | 1.81 | $1,121,889 | $242,484 |
| 2019 | 479 | 2,995 | 77 | 2.05 | $1,162,387 | $255,464 |
| 2018 | 502 | 3,303 | 77 | 1.98 | $1,299,573 | $340,039 |
| 2017 | 413 | 2,676 | 77 | 1.93 | $1,023,747 | $289,082 |
| 2016 | 367 | 2,038 | 76 | 1.85 | $662,777 | $204,115 |
| 2015 | 255 | 1,518 | 76 | 1.84 | $472,936 | $154,680 |
| 2013 | 34 | 82 | 72 | 1.64 | $50,087 | $7,282 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 16 services
| Long return visit (40+ min) | 229 | $133,366 | $127 |
| Return visit (30+ min) | 367 | $66,667 | $83 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 85 | $64,105 | $109 |
| Telephone medical discussion with physician, 21-30 minutes | 103 | $20,873 | $115 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 108 | $18,447 | $117 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 70 | $16,587 | $73 |
| New patient visit (60+ min) | 86 | $13,400 | $156 |
| Return visit (30+ min) | 67 | $12,735 | $117 |
| Long return visit (40+ min) | 20 | $5,389 | $174 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 23 | $4,393 | $146 |
| New patient visit (45+ min) | 20 | $2,402 | $120 |
| Telephone medical discussion with physician, 21-30 minutes | 24 | $2,246 | $86 |
| Hospital discharge day management, more than 30 minutes | 15 | $1,901 | $106 |
| Short return visit (20+ min) | 12 | $1,065 | $89 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 12 | $811 | $45 |
| Short return visit (20+ min) | 14 | $791 | $49 |
2022: 12 services
| Return visit (30+ min) | 389 | $112,934 | $83 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 130 | $89,320 | $94 |
| Telephone medical discussion with physician, 21-30 minutes | 244 | $60,945 | $115 |
| Long return visit (40+ min) | 129 | $47,293 | $129 |
| New patient visit (60+ min) | 85 | $13,128 | $154 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 94 | $12,404 | $92 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 46 | $6,641 | $125 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 24 | $4,761 | $183 |
| Short return visit (20+ min) | 41 | $3,716 | $55 |
| Hospital discharge day management, more than 30 minutes | 19 | $2,270 | $99 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 20 | $1,970 | $68 |
| Telephone medical discussion with physician, 21-30 minutes | 15 | $1,129 | $75 |
2021: 14 services
| Return visit (30+ min) | 358 | $113,580 | $87 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 140 | $75,092 | $96 |
| Long return visit (40+ min) | 150 | $55,157 | $129 |
| Telephone medical discussion with physician, 21-30 minutes | 185 | $44,776 | $120 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 86 | $21,091 | $174 |
| New patient visit (60+ min) | 71 | $11,868 | $167 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 54 | $9,381 | $125 |
| Short return visit (20+ min) | 72 | $5,717 | $57 |
| Hospital discharge day management, more than 30 minutes | 18 | $2,818 | $97 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 17 | $1,903 | $68 |
| Telephone medical discussion with physician, 11-20 minutes | 23 | $1,822 | $76 |
| Telephone medical discussion with physician, 21-30 minutes | 15 | $1,405 | $88 |
| Biopsy and aspiration of bone marrow sample for diagnosis | 12 | $951 | $73 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 12 | $534 | $33 |
2020: 11 services
| Return visit (30+ min) | 331 | $80,591 | $66 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 99 | $61,901 | $96 |
| Long return visit (40+ min) | 123 | $39,845 | $99 |
| Telephone medical discussion with physician, 21-30 minutes | 117 | $19,536 | $101 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 47 | $10,089 | $177 |
| New patient visit (60+ min) | 64 | $9,203 | $144 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 36 | $6,946 | $114 |
| Short return visit (20+ min) | 51 | $4,081 | $43 |
| Hospital discharge day management, more than 30 minutes | 19 | $2,620 | $87 |
| Telephone medical discussion with physician, 11-20 minutes | 27 | $2,237 | $70 |
| Hospital discharge day management, 30 minutes or less | 11 | $1,164 | $68 |
2019: 11 services
| Return visit (30+ min) | 361 | $97,364 | $70 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 131 | $64,687 | $95 |
| Long return visit (40+ min) | 159 | $51,413 | $100 |
| New patient visit (60+ min) | 67 | $10,203 | $152 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 44 | $8,329 | $181 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 32 | $5,094 | $124 |
| Return visit (30+ min) | 55 | $4,661 | $80 |
| Follow-up observation care per day, typically 35 minutes | 18 | $3,544 | $93 |
| Short return visit (20+ min) | 35 | $3,416 | $43 |
| Long return visit (40+ min) | 13 | $1,727 | $133 |
| Hospital discharge day management, 30 minutes or less | 11 | $814 | $68 |
2018: 7 services
| Return visit (30+ min) | 399 | $168,549 | $97 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 134 | $77,424 | $94 |
| Long return visit (40+ min) | 158 | $54,060 | $133 |
| New patient visit (60+ min) | 79 | $14,834 | $188 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 63 | $11,408 | $181 |
| Short return visit (20+ min) | 72 | $10,483 | $67 |
| Hospital discharge day management, 30 minutes or less | 18 | $1,337 | $67 |
2017: 7 services
| Return visit (30+ min) | 261 | $115,378 | $100 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 124 | $68,561 | $92 |
| Long return visit (40+ min) | 167 | $65,225 | $134 |
| New patient visit (60+ min) | 82 | $15,391 | $188 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 84 | $15,216 | $181 |
| Short return visit (20+ min) | 43 | $4,664 | $67 |
| Hospital discharge day management, 30 minutes or less | 15 | $1,938 | $65 |
2016: 7 services
| Return visit (30+ min) | 226 | $106,777 | $95 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 106 | $49,768 | $90 |
| New patient visit (60+ min) | 103 | $18,687 | $181 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 61 | $10,974 | $174 |
| Long return visit (40+ min) | 55 | $9,370 | $130 |
| Short return visit (20+ min) | 64 | $4,690 | $63 |
| Hospital discharge day management, 30 minutes or less | 13 | $1,031 | $64 |
2015: 7 services
| Return visit (30+ min) | 159 | $70,980 | $101 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 99 | $45,616 | $93 |
| New patient visit (60+ min) | 72 | $13,404 | $186 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 54 | $9,763 | $181 |
| Return visit (30+ min) | 49 | $4,112 | $65 |
| Long return visit (40+ min) | 22 | $3,112 | $135 |
| Short return visit (20+ min) | 33 | $3,022 | $69 |
2013: 2 services
| Long return visit (40+ min) | 23 | $5,036 | $84 |
| New patient visit (60+ min) | 18 | $2,195 | $122 |
Medicaid work
$789 in 2024
Medicaid paid $789 for 153 billed services this clinician did in 2024, up to 17 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Long return visit (40+ min) | 153 | $789 |
| 2024 | 153 | 1 | 17 | $789 |
| 2023 | 92 | 2 | 14 | $669 |
| 2022 | 139 | 1 | 24 | $1,131 |
| 2021 | 112 | 1 | 16 | $588 |
| 2020 | 75 | 1 | 21 | $553 |
| 2019 | 146 | 2 | 19 | $705 |
| 2018 | 314 | 2 | 27 | $6,647 |
See the largest Medicaid services in earlier years
2023
| Return visit (30+ min) | 15 | $338 |
| Long return visit (40+ min) | 77 | $332 |
2022
| Return visit (30+ min) | 139 | $1,131 |
2021
| Return visit (30+ min) | 112 | $588 |
2020
| Return visit (30+ min) | 75 | $553 |
2019
| Return visit (30+ min) | 133 | $609 |
| Long return visit (40+ min) | 13 | $96 |
2018
| Return visit (30+ min) | 256 | $5,162 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 58 | $1,485 |
Drugs they prescribed that Part D paid
$6,269,115
Pharmacies billed $6,269,115 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 5% of their Part D prescriptions (129 of 2,683) in 2024. At or below the middle of the specialty; the typical hematology-oncology clinician is at 5%. Long-acting opioids: 19% of their opioid prescriptions.
1,962 generic and fewer than 11 brand-name prescriptions · $6,269,115 in drug cost · 44 antibiotic prescriptions to 29 people · 13 antipsychotic prescriptions to people over 65.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Lenvima | 37 | $889,782 | $24,048 |
| Tagrisso | 47 | $769,171 | $16,365 |
| Cabometyx | 13 | $594,166 | $45,705 |
| Verzenio | 40 | $574,191 | $14,355 |
| Revlimid | 29 | $463,160 | $15,971 |
See all 63 drugs
| Lenvima | 37 | $889,782 | $24,048 |
| Tagrisso | 47 | $769,171 | $16,365 |
| Cabometyx | 13 | $594,166 | $45,705 |
| Verzenio | 40 | $574,191 | $14,355 |
| Revlimid | 29 | $463,160 | $15,971 |
| Imbruvica | 31 | $459,226 | $14,814 |
| Lynparza | 30 | $434,569 | $14,486 |
| Ibrance | 28 | $390,418 | $13,943 |
| Brukinsa | 15 | $226,117 | $15,074 |
| Lenalidomide | 20 | $216,971 | $10,849 |
| Xtandi | 12 | $176,595 | $14,716 |
| Eliquis | 151 | $119,595 | $792 |
| Stivarga | 11 | $61,786 | $5,617 |
| Imatinib Mesylate | 38 | $56,558 | $1,488 |
| Orgovyx | 14 | $37,682 | $2,692 |
| Xarelto | 20 | $21,337 | $1,067 |
| Abiraterone Acetate | 13 | $20,165 | $1,551 |
| Creon | 21 | $18,591 | $885 |
| Exemestane | 95 | $18,353 | $193 |
| Linzess | 12 | $9,563 | $797 |
| Megestrol Acetate | 45 | $2,179 | $48 |
| Levothyroxine | 85 | $2,170 | $26 |
| Anastrozole | 126 | $2,009 | $16 |
| Hydrocodone-Acetaminophen | 53 | $1,544 | $29 |
| Hydroxyurea | 58 | $1,192 | $21 |
| Ursodiol | 16 | $1,192 | $74 |
| Letrozole | 67 | $1,031 | $15 |
| Ondansetron | 42 | $999 | $24 |
| Pantoprazole | 82 | $946 | $12 |
| Hydrocortisone | 39 | $848 | $22 |
| Bicalutamide | 22 | $738 | $34 |
| Tamoxifen Citrate | 38 | $682 | $18 |
| Nystatin | 26 | $587 | $23 |
| Potassium Chloride | 48 | $562 | $12 |
| Erlotinib | 12 | $532 | $44 |
| Venlafaxine Hcl Er | 18 | $529 | $29 |
| Prednisone | 84 | $525 | $6 |
| Morphine Sulfate Er | 18 | $520 | $29 |
| Gabapentin | 43 | $485 | $11 |
| Diphenoxylate-Atropine | 19 | $482 | $25 |
| Lorazepam | 65 | $430 | $7 |
| Dexamethasone | 17 | $341 | $20 |
| Morphine Sulfate | 13 | $328 | $25 |
| Tenofovir Disoproxil | 11 | $287 | $26 |
| Acyclovir | 24 | $282 | $12 |
| Furosemide | 77 | $274 | $4 |
| Zolpidem | 55 | $270 | $5 |
| Warfarin | 18 | $217 | $12 |
| Trazodone | 77 | $211 | $3 |
| Metoprolol | 15 | $209 | $14 |
| Oxycodone | 17 | $208 | $12 |
| Losartan | 19 | $207 | $11 |
| Omeprazole | 17 | $194 | $11 |
| Alprazolam | 20 | $131 | $7 |
| Hydroxyzine | 11 | $130 | $12 |
| Metoclopramide | 32 | $128 | $4 |
| Amlodipine Besylate | 29 | $118 | $4 |
| Folic Acid | 12 | $110 | $9 |
| Metformin | 11 | $66 | $6 |
| Lisinopril | 14 | $43 | $3 |
| Azithromycin | 14 | $33 | $2 |
| Alendronate | 18 | $31 | $2 |
| Ibuprofen | 11 | $22 | $2 |
Year by year
| 2024 | 2,683 | 358 | 5% (129) | None | $6,269,115 |
| 2023 | 1,596 | 273 | 6% (91) | None | $2,683,890 |
| 2022 | 1,090 | 210 | 4% (46) | None | $1,704,448 |
| 2021 | 1,136 | 201 | 6% (72) | None | $1,769,621 |
| 2020 | 1,283 | 186 | 6% (72) | None | $1,713,312 |
| 2019 | 1,496 | 229 | 5% (69) | None | $2,410,114 |
| 2018 | 2,100 | 247 | 5% (108) | 26% | $3,626,944 |
| 2017 | 1,423 | 172 | 4% (60) | None | $1,749,281 |
| 2016 | 983 | 130 | 7% (66) | None | $1,341,744 |
| 2015 | 717 | 92 | 8% (57) | 28% | $594,084 |
| 2014 | 339 | 65 | 9% (29) | 22% | $177,761 |
| 2013 | 227 | 47 | 5% (11) | 12% | $24,484 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 45 drugs
| Lenvima | 25 | $599,257 | $23,970 |
| Lenalidomide | 19 | $243,661 | $12,824 |
| Revlimid | 14 | $240,263 | $17,162 |
| Xtandi | 11 | $119,618 | $10,874 |
| Abiraterone Acetate | 11 | $90,483 | $8,226 |
| Eliquis | 59 | $46,263 | $784 |
| Linzess | 21 | $12,866 | $613 |
| Exemestane | 35 | $6,464 | $185 |
| Tenofovir Disoproxil | 12 | $2,244 | $187 |
| Megestrol Acetate | 27 | $2,088 | $77 |
| Hydroxyurea | 43 | $1,374 | $32 |
| Anastrozole | 34 | $1,214 | $36 |
| Pantoprazole | 54 | $1,036 | $19 |
| Levothyroxine | 45 | $928 | $21 |
| Ursodiol | 19 | $869 | $46 |
| Letrozole | 32 | $830 | $26 |
| Potassium Chloride | 38 | $725 | $19 |
| Hydrocodone-Acetaminophen | 24 | $668 | $28 |
| Ondansetron | 21 | $655 | $31 |
| Lorazepam | 54 | $567 | $10 |
| Tamoxifen Citrate | 16 | $529 | $33 |
| Prednisone | 72 | $495 | $7 |
| Morphine Sulfate Er | 16 | $493 | $31 |
| Diphenoxylate-Atropine | 19 | $464 | $24 |
| Sodium Chloride | 23 | $453 | $20 |
| Losartan | 16 | $443 | $28 |
| Bicalutamide | 13 | $357 | $27 |
| Albuterol Sulfate Hfa | 14 | $356 | $25 |
| Amlodipine Besylate | 19 | $349 | $18 |
| Oxycodone | 22 | $346 | $16 |
| Dexamethasone | 25 | $337 | $13 |
| Acyclovir | 18 | $299 | $17 |
| Gabapentin | 25 | $288 | $12 |
| Trazodone | 33 | $283 | $9 |
| Zolpidem | 42 | $265 | $6 |
| Hydrocortisone | 15 | $264 | $18 |
| Furosemide | 38 | $208 | $5 |
| Venlafaxine Hcl Er | 22 | $162 | $7 |
| Metoclopramide | 12 | $161 | $13 |
| Ciprofloxacin | 12 | $108 | $9 |
| Lisinopril | 13 | $102 | $8 |
| Alprazolam | 14 | $93 | $7 |
| Metformin | 11 | $77 | $7 |
| Azithromycin | 12 | $62 | $5 |
| Metoprolol | 11 | $61 | $6 |
2022: 29 drugs
| Revlimid | 50 | $912,745 | $18,255 |
| Eliquis | 30 | $18,258 | $609 |
| Xarelto | 21 | $12,931 | $616 |
| Ursodiol | 13 | $3,257 | $251 |
| Exemestane | 17 | $2,455 | $144 |
| Megestrol Acetate | 27 | $1,638 | $61 |
| Ondansetron | 21 | $853 | $41 |
| Potassium Chloride | 27 | $694 | $26 |
| Pantoprazole | 53 | $575 | $11 |
| Hydrocodone-Acetaminophen | 18 | $494 | $27 |
| Tamoxifen Citrate | 16 | $444 | $28 |
| Gabapentin | 35 | $439 | $13 |
| Hydroxyurea | 11 | $435 | $40 |
| Prednisone | 65 | $407 | $6 |
| Bicalutamide | 12 | $357 | $30 |
| Dexamethasone | 18 | $348 | $19 |
| Diphenoxylate-Atropine | 11 | $347 | $32 |
| Lorazepam | 47 | $278 | $6 |
| Letrozole | 20 | $269 | $13 |
| Oxycodone-Acetaminophen | 11 | $252 | $23 |
| Zolpidem | 22 | $198 | $9 |
| Dicyclomine | 12 | $190 | $16 |
| Levothyroxine | 16 | $170 | $11 |
| Metoclopramide | 18 | $145 | $8 |
| Hydrocortisone | 13 | $131 | $10 |
| Trazodone | 22 | $118 | $5 |
| Furosemide | 27 | $104 | $4 |
| Atorvastatin | 16 | $103 | $6 |
| Lisinopril | 11 | $27 | $2 |
2021: 31 drugs
| Revlimid | 49 | $839,950 | $17,142 |
| Tagrisso | 16 | $264,001 | $16,500 |
| Ibrance | 12 | $155,692 | $12,974 |
| Eliquis | 26 | $16,724 | $643 |
| Creon | 13 | $14,248 | $1,096 |
| Exemestane | 16 | $2,351 | $147 |
| Lidocaine | 14 | $2,175 | $155 |
| Potassium Chloride | 31 | $1,488 | $48 |
| Hydroxyurea | 14 | $1,172 | $84 |
| Letrozole | 22 | $942 | $43 |
| Dexamethasone | 41 | $923 | $23 |
| Hydrocodone-Acetaminophen | 33 | $839 | $25 |
| Megestrol Acetate | 19 | $777 | $41 |
| Ondansetron | 15 | $681 | $45 |
| Pantoprazole | 46 | $621 | $14 |
| Tamoxifen Citrate | 19 | $609 | $32 |
| Levothyroxine | 31 | $573 | $18 |
| Hydrocortisone | 24 | $557 | $23 |
| Lorazepam | 55 | $359 | $7 |
| Prednisone | 45 | $293 | $7 |
| Diphenoxylate-Atropine | 11 | $247 | $22 |
| Furosemide | 38 | $208 | $5 |
| Anastrozole | 14 | $192 | $14 |
| Alprazolam | 12 | $157 | $13 |
| Allopurinol | 11 | $135 | $12 |
| Gabapentin | 15 | $91 | $6 |
| Metoclopramide | 17 | $88 | $5 |
| Zolpidem | 16 | $82 | $5 |
| Trazodone | 15 | $73 | $5 |
| Metoprolol | 11 | $56 | $5 |
| Amlodipine Besylate | 12 | $46 | $4 |
2020: 35 drugs
| Revlimid | 26 | $517,350 | $19,898 |
| Tagrisso | 24 | $383,730 | $15,989 |
| Ibrance | 18 | $228,281 | $12,682 |
| Erlotinib | 13 | $68,761 | $5,289 |
| Eliquis | 38 | $18,029 | $474 |
| Exemestane | 50 | $15,266 | $305 |
| Lidocaine | 12 | $2,346 | $195 |
| Tamoxifen Citrate | 23 | $1,607 | $70 |
| Clindamycin Phosphate | 13 | $1,353 | $104 |
| Bicalutamide | 22 | $1,349 | $61 |
| Megestrol Acetate | 24 | $1,076 | $45 |
| Hydroxyurea | 25 | $928 | $37 |
| Pregabalin | 12 | $716 | $60 |
| Nystatin | 30 | $699 | $23 |
| Hydrocortisone | 26 | $679 | $26 |
| Potassium Chloride | 42 | $666 | $16 |
| Minocycline | 15 | $637 | $42 |
| Ondansetron | 23 | $548 | $24 |
| Dexamethasone | 29 | $539 | $19 |
| Hydrocodone-Acetaminophen | 22 | $526 | $24 |
| Lorazepam | 56 | $471 | $8 |
| Pantoprazole | 25 | $471 | $19 |
| Lidocaine Hcl Viscous | 14 | $455 | $33 |
| Letrozole | 17 | $449 | $26 |
| Anastrozole | 25 | $449 | $18 |
| Triamcinolone Acetonide | 11 | $432 | $39 |
| Prednisone | 57 | $374 | $7 |
| Levothyroxine | 15 | $285 | $19 |
| Furosemide | 48 | $212 | $4 |
| Levofloxacin | 11 | $194 | $18 |
| Gabapentin | 16 | $185 | $12 |
| Zolpidem | 30 | $143 | $5 |
| Metoclopramide | 15 | $93 | $6 |
| Amlodipine Besylate | 23 | $82 | $4 |
| Ciprofloxacin | 11 | $48 | $4 |
2019: 40 drugs
| Revlimid | 39 | $726,525 | $18,629 |
| Tagrisso | 29 | $450,022 | $15,518 |
| Ibrance | 16 | $181,358 | $11,335 |
| Imbruvica | 12 | $138,676 | $11,556 |
| Imatinib Mesylate | 23 | $119,647 | $5,202 |
| Xtandi | 12 | $97,985 | $8,165 |
| Exemestane | 83 | $21,311 | $257 |
| Eliquis | 30 | $14,523 | $484 |
| Xarelto | 16 | $11,146 | $697 |
| Lidocaine | 20 | $3,141 | $157 |
| Tamoxifen Citrate | 53 | $1,518 | $29 |
| Megestrol Acetate | 22 | $1,378 | $63 |
| Amoxicillin-Clavulanate Potass | 17 | $1,325 | $78 |
| Minocycline | 12 | $1,129 | $94 |
| Potassium Chloride | 41 | $1,089 | $27 |
| Pantoprazole | 55 | $1,052 | $19 |
| Anastrozole | 58 | $1,012 | $17 |
| Droxia | 23 | $951 | $41 |
| Hydroxyurea | 23 | $764 | $33 |
| Bicalutamide | 28 | $675 | $24 |
| Dexamethasone | 18 | $538 | $30 |
| Levothyroxine | 32 | $526 | $16 |
| Hydrocodone-Acetaminophen | 22 | $522 | $24 |
| Lorazepam | 61 | $503 | $8 |
| Nystatin | 16 | $386 | $24 |
| Prednisone | 46 | $313 | $7 |
| Ondansetron | 18 | $287 | $16 |
| Letrozole | 15 | $256 | $17 |
| Zolpidem | 20 | $256 | $13 |
| Hydrocortisone | 19 | $216 | $11 |
| Gabapentin | 18 | $214 | $12 |
| Alprazolam | 22 | $213 | $10 |
| Furosemide | 44 | $200 | $5 |
| Atorvastatin | 20 | $178 | $9 |
| Amlodipine Besylate | 23 | $162 | $7 |
| Tamsulosin | 14 | $158 | $11 |
| Omeprazole | 13 | $119 | $9 |
| Oxycodone | 13 | $113 | $9 |
| Losartan | 21 | $109 | $5 |
| Ciprofloxacin | 14 | $86 | $6 |
2018: 49 drugs
| Revlimid | 69 | $973,441 | $14,108 |
| Tagrisso | 31 | $470,892 | $15,190 |
| Ibrance | 39 | $457,474 | $11,730 |
| Afinitor | 18 | $298,008 | $16,556 |
| Imbruvica | 20 | $258,961 | $12,948 |
| Tarceva | 29 | $238,484 | $8,224 |
| Xtandi | 19 | $162,953 | $8,576 |
| Tafinlar | 11 | $103,804 | $9,437 |
| Imatinib Mesylate | 11 | $84,198 | $7,654 |
| Exemestane | 114 | $39,859 | $350 |
| Xarelto | 45 | $23,610 | $525 |
| Eliquis | 39 | $18,450 | $473 |
| Lidocaine | 27 | $6,125 | $227 |
| Anagrelide | 12 | $3,898 | $325 |
| Potassium Chloride | 60 | $3,004 | $50 |
| Anastrozole | 100 | $1,779 | $18 |
| Tamoxifen Citrate | 41 | $1,648 | $40 |
| Hydroxyurea | 46 | $1,271 | $28 |
| Ondansetron | 54 | $1,143 | $21 |
| Megestrol Acetate | 30 | $924 | $31 |
| Diphenoxylate-Atropine | 12 | $807 | $67 |
| Oxycodone-Acetaminophen | 13 | $795 | $61 |
| Nystatin | 29 | $683 | $24 |
| Pantoprazole | 66 | $656 | $10 |
| Dexamethasone | 39 | $601 | $15 |
| Hydrocodone-Acetaminophen | 25 | $580 | $23 |
| Zolpidem | 54 | $498 | $9 |
| Letrozole | 51 | $489 | $10 |
| Oxycodone | 27 | $414 | $15 |
| Valsartan | 11 | $378 | $34 |
| Lorazepam | 85 | $367 | $4 |
| Amoxicillin-Clavulanate Potass | 12 | $359 | $30 |
| Hydrocortisone | 26 | $343 | $13 |
| Levothyroxine | 33 | $316 | $10 |
| Gabapentin | 36 | $274 | $8 |
| Tamsulosin | 27 | $271 | $10 |
| Prednisone | 40 | $248 | $6 |
| Diazepam | 12 | $220 | $18 |
| Minocycline | 11 | $196 | $18 |
| Metoclopramide | 36 | $194 | $5 |
| Levofloxacin | 15 | $175 | $12 |
| Venlafaxine Hcl Er | 15 | $166 | $11 |
| Alprazolam | 19 | $139 | $7 |
| Tramadol | 19 | $121 | $6 |
| Ibuprofen | 13 | $121 | $9 |
| Amlodipine Besylate | 31 | $120 | $4 |
| Furosemide | 41 | $98 | $2 |
| Azithromycin | 15 | $88 | $6 |
| Simvastatin | 16 | $52 | $3 |
2017: 37 drugs
| Revlimid | 47 | $657,911 | $13,998 |
| Tarceva | 50 | $361,672 | $7,233 |
| Imbruvica | 15 | $177,153 | $11,810 |
| Xarelto | 63 | $27,701 | $440 |
| Exemestane | 45 | $21,034 | $467 |
| Entecavir | 13 | $11,798 | $908 |
| Eliquis | 19 | $8,928 | $470 |
| Potassium Chloride | 48 | $1,558 | $32 |
| Anagrelide | 14 | $1,215 | $87 |
| Ondansetron | 41 | $1,158 | $28 |
| Pantoprazole | 91 | $1,146 | $13 |
| Clindamycin Phosphate | 13 | $1,065 | $82 |
| Anastrozole | 65 | $1,045 | $16 |
| Diphenoxylate-Atropine | 20 | $920 | $46 |
| Hydroxyurea | 45 | $909 | $20 |
| Nystatin | 24 | $863 | $36 |
| Levofloxacin | 17 | $734 | $43 |
| Oxycodone | 25 | $565 | $23 |
| Minocycline | 18 | $492 | $27 |
| Triamcinolone Acetonide | 18 | $384 | $21 |
| Dexamethasone | 25 | $365 | $15 |
| Hydrocortisone | 19 | $351 | $18 |
| Levothyroxine | 16 | $348 | $22 |
| Gabapentin | 23 | $309 | $13 |
| Letrozole | 35 | $301 | $9 |
| Loperamide | 12 | $292 | $24 |
| Lorazepam | 54 | $291 | $5 |
| Ondansetron Odt | 12 | $290 | $24 |
| Prednisone | 32 | $227 | $7 |
| Tamsulosin | 14 | $225 | $16 |
| Zolpidem | 25 | $192 | $8 |
| Venlafaxine Hcl Er | 18 | $144 | $8 |
| Furosemide | 23 | $107 | $5 |
| Metoclopramide | 27 | $100 | $4 |
| Amlodipine Besylate | 13 | $94 | $7 |
| Azithromycin | 13 | $75 | $6 |
| Simvastatin | 18 | $35 | $2 |
2016: 27 drugs
| Revlimid | 33 | $399,666 | $12,111 |
| Tarceva | 52 | $341,185 | $6,561 |
| Imbruvica | 19 | $197,884 | $10,415 |
| Nexavar | 11 | $96,131 | $8,739 |
| Xarelto | 35 | $13,753 | $393 |
| Eliquis | 26 | $10,440 | $402 |
| Exemestane | 34 | $9,036 | $266 |
| Ondansetron | 30 | $1,035 | $34 |
| Anagrelide | 13 | $975 | $75 |
| Hydrocodone-Acetaminophen | 34 | $956 | $28 |
| Warfarin | 21 | $756 | $36 |
| Dexamethasone | 46 | $699 | $15 |
| Voltaren | 14 | $692 | $49 |
| Anastrozole | 42 | $647 | $15 |
| Hydroxyurea | 35 | $568 | $16 |
| Potassium Chloride | 18 | $406 | $23 |
| Pantoprazole | 27 | $357 | $13 |
| Oxycodone | 17 | $322 | $19 |
| Lorazepam | 44 | $265 | $6 |
| Levofloxacin | 19 | $208 | $11 |
| Gabapentin | 22 | $197 | $9 |
| Hydrocortisone | 13 | $169 | $13 |
| Acyclovir | 11 | $113 | $10 |
| Prednisone | 15 | $91 | $6 |
| Metoclopramide | 18 | $70 | $4 |
| Furosemide | 11 | $26 | $2 |
| Hydrochlorothiazide | 11 | $21 | $2 |
2015: 27 drugs
| Tarceva | 34 | $181,139 | $5,328 |
| Imbruvica | 15 | $150,715 | $10,048 |
| Xarelto | 35 | $13,258 | $379 |
| Exemestane | 21 | $5,492 | $262 |
| Tradjenta | 12 | $3,994 | $333 |
| Advair Diskus | 12 | $3,703 | $309 |
| Repaglinide | 13 | $1,401 | $108 |
| Dronabinol | 12 | $1,064 | $89 |
| Fentanyl | 11 | $700 | $64 |
| Hydroxyurea | 21 | $675 | $32 |
| Ondansetron | 25 | $529 | $21 |
| Dexamethasone | 26 | $425 | $16 |
| Oxycodone | 17 | $418 | $25 |
| Zolpidem | 13 | $342 | $26 |
| Anastrozole | 28 | $341 | $12 |
| Levothyroxine | 15 | $323 | $22 |
| Lorazepam | 44 | $220 | $5 |
| Hydrocodone-Acetaminophen | 13 | $217 | $17 |
| Levofloxacin | 15 | $153 | $10 |
| Prednisone | 22 | $128 | $6 |
| Gabapentin | 20 | $123 | $6 |
| Acyclovir | 13 | $102 | $8 |
| Potassium Chloride | 11 | $98 | $9 |
| Furosemide | 22 | $85 | $4 |
| Amlodipine Besylate | 13 | $79 | $6 |
| Hydrochlorothiazide | 14 | $42 | $3 |
| Simvastatin | 11 | $20 | $2 |
2014: 6 drugs
| Xarelto | 18 | $5,957 | $331 |
| Anastrozole | 39 | $1,238 | $32 |
| Ondansetron | 22 | $317 | $14 |
| Dexamethasone | 12 | $167 | $14 |
| Prednisone | 22 | $142 | $6 |
| Azithromycin | 13 | $114 | $9 |
2013: 3 drugs
| Exemestane | 34 | $8,096 | $238 |
| Anastrozole | 52 | $2,207 | $42 |
| Letrozole | 23 | $492 | $21 |
Money from drug and device companies
$74 in 2025
| 2025 | 2 | 2 | None | $74 |
| 2023 | 2 | 2 | None | $38 |
| 2022 | 3 | 3 | None | $74 |
| 2021 | 1 | 1 | None | $12 |
| 2020 | 13 | 15 | None | $317 |
| 2019 | 19 | 70 | None | $1,352 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| AstraZeneca Pharmaceuticals LP | Enhertu | $43 | 1 payment
|
| Pfizer | Ibrance | $31 | 1 payment
|
See all 2 published payments
| AstraZeneca Pharmaceuticals LP | Education · 2025-11-19 | Enhertu | $43 |
| Pfizer | Education · 2025-07-10 | Ibrance | $31 |
See earlier years (2023, 2022, 2021, 2020, 2019)
2023: $38
| Pfizer | Ibrance | $25 | 1 payment
|
| Janssen Pharmaceuticals | None | $13 | 1 payment
|
2022: $74
| Seagen | Padcev | $41 | 1 payment
|
| Novartis Pharmaceuticals | None | $22 | 1 payment
|
| Merck Sharp & Dohme | Keytruda | $11 | 1 payment
|
2021: $12
| Gilead Sciences | None | $12 | 1 payment
|
2020: $317
| Seagen | Adcetris | $54 | 2 payments
|
| AstraZeneca Pharmaceuticals LP | Lynparza | $36 | 2 payments
|
| Eisai | Lenvima | $27 | 1 payment
|
| Blueprint Medicines | Ayvakit | $25 | 1 payment
|
| Pfizer | Xtandi | $24 | 1 payment
|
| Lilly USA | Alimta | $22 | 1 payment
|
| Bayer HealthCare Pharmaceuticals | Nubeqa | $22 | 1 payment
|
| Merck Sharp & Dohme | Keytruda | $20 | 1 payment
|
| Novartis Pharmaceuticals | Tasigna | $20 | 1 payment
|
| Janssen Biotech | Darzalex | $18 | 1 payment
|
| Puma Biotechnology | Nerlynx | $17 | 1 payment
|
| Celgene | Revlimid | $17 | 1 payment
|
| Foundation Medicine | Foundationone | $16 | 1 payment
|
2019: $1,352
| Novartis Pharmaceuticals | Votrient | $157 | 8 payments
|
| Lilly USA | Alimta | $155 | 8 payments
|
| E.R. Squibb & Sons L.L.C. | Opdivo | $151 | 8 payments
|
| Takeda Pharmaceuticals U.S.A. | None | $138 | 5 payments
|
| Merck Sharp & Dohme | Keytruda | $125 | 7 payments
|
| Pfizer | Ibrance | $81 | 5 payments
|
| Bayer HealthCare Pharmaceuticals | Xofigo | $74 | 4 payments
|
| AstraZeneca Pharmaceuticals LP | Imfinzi | $72 | 4 payments
|
| Amgen | Nplate | $53 | 2 payments
|
| Incyte | Jakafi | $52 | 3 payments
|
| Rigel Pharmaceuticals | Tavalisse | $51 | 2 payments
|
| Celgene | Revlimid | $49 | 3 payments
|
| EMD Serono | Bavencio | $46 | 3 payments
|
| Tesaro | Zejula | $42 | 2 payments
|
| Seattle Genetics | Adcetris | $42 | 2 payments
|
| Janssen Biotech | Darzalex | $24 | 1 payment
|
| Eisai | Halaven | $16 | 1 payment
|
| Foundation Medicine | Foundationone | $13 | 1 payment
|
| Clovis Oncology | Rubraca | $12 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Merck Sharp & Dohme Corporation · A Randomized, Double-Blind, Phase III Study of Pembrolizumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Er,Her2 Breast Cancer Keynote-756 · 2021 | Their institution | $62,972 |
| Merck Sharp & Dohme Corporation · A Randomized, Double-Blind, Phase III Study of Pembrolizumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Er,Her2- Breast Cancer Keynote-756 · 2019 | Their institution | $53,306 |
| Merck Sharp & Dohme Corporation · A Randomized, Double-Blind, Phase III Study of Pembrolizumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Er,Her2- Breast Cancer Keynote-756 · 2020 | Their institution | $21,186 |
| Merck Sharp & Dohme LLC · A Randomized, Double-Blind, Phase III Study of Pembrolizumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Er,Her2 Breast Cancer Keynote-756 · 2022 | Their institution | $14,038 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 83.6 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1396981445
- Licence
- CA A105831California A105831: Current · expires 2026-10-31
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RH0003X (207RH0003X)
- Mailing address
- 2505 Hospital Dr, Mountain View, CA, 94040
- NPI first listed
- 2008-12-19
- NPI last updated
- 2020-11-30
- NPI record certified
- 2020-11-30
This is when the NPI record was last certified, not a medical board exam.